Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Belle Health vs Henry Meds

Belle Health
Graded #48

Lower grade

vs+0.29999999999999716
Henry Meds
Graded #46

Higher grade

The verdict

Henry Meds takes it — 77.3/100 to 77/100, but only just.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A flat-fee compounded pioneer — simple, but priced at the higher end of the board now. Belle Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBelle Health +20
92
72
Dose & formulationHenry Meds +8
72
80
Clinical oversightHenry Meds +9
71
80
Labs & monitoringHenry Meds +6
72
78
FulfillmentBelle Health +7
85
78
Contract termsHenry Meds +23
55
78
Belle Health · left barHenry Meds · right bar

The numbers

MetricBelle HealthHenry Meds
WeighScore77/10077.3/100
GradeC+C+
Scorecard rank#48#46
Semaglutide$119/mo$249/mo
Tirzepatide$199/mo (all doses, 3-month plan, compounded)$349/mo
CoverageAll 50 statesMulti-state
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Belle Health

Graded #48 · C+

Strengths

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

Where it loses points

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Henry Meds

Graded #46 · C+

Strengths

  • Simple flat-fee model
  • Established brand
  • Both molecules

Where it loses points

  • Higher pricing than newer entrants
  • Compounded only

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard